16 HCV abstracts to be presented including 12 data presentations on the safety and efficacy of MAVYRET MAVYRET is recommended in new AASLD guidelines as a first line treatment option for 8 weeks in treatment-naïve non-cirrhotic HCV patients across all genotypes (GT1-6) Glecaprevir, one of the two new, direct-acting antivirals (DAAs) in MAVYRET, is Enanta's second protease inhibitor being developed and commercialized by AbbVie WATERTOWN, Mass.--(BUSINESS WIRE)--Oct. 11, 2017-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced, that AbbVie will...
↧